Topiramate

Preview FDA label, Par Health USA, LLC, oral, effective 2026-05-27. Full label on DailyMed

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.

Dosing in kidney impairment

Dose Modifications in Patients With Renal Impairment In patients with renal impairment (creatinine clearance less than 70 mL/min/1.73 m 2 ), one-half of the usual adult dose of topiramate extended-release capsules are recommended [see Use in Specific Populations ( 8.5 , 8.6 ) , Clinical Pharmacology] .

Dosage Modifications in Patients Undergoing Hemodialysis To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate extended-release capsules may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed [see Use in Specific Populations, Clinical Pharmacology] .

Preparation and administration

Administration With Alcohol Alcohol use should be completely avoided within 6 hours prior to and 6 hours after topiramate extended-release capsules administration [see Warnings and Precautions] .

Administration Instructions Topiramate extended-release capsules can be taken without regard to meals. Swallow capsule whole and intact. Do not sprinkle on food, chew, or crush.

Calculators for topiramate